The access-to-medicines folks as well as Big Pharma backers will want to take note of the latest ‘issue’ arising in the pharmaeutical pricing arena. As we had reported earlier last year, Roche had decided to drop its pursuance of patents over breast cancer biologics drug Herceptin (Trastuzumab). However, if anyone thought this meant a cheaply available generic would soon be available, it turns out that they’d be mistaken. US-based Mylan along with partner Bangalore-based Biocon received regulatory approval a few...
↧